Cellebrite Earnings Call Highlights AI-Fueled Growth

Cellebrite Di Ltd. ((CLBT)) has held its Q1 earnings call. Read on for the main highlights of the call.

Cellebrite Di Ltd. struck an upbeat tone on its latest earnings call, spotlighting strong subscription growth, expanding margins and mounting investor interest in its new AI‑driven investigation tools. Executives acknowledged seasonal softness, FX pressure and execution risks around monetizing early AI adoption, but argued that robust cash generation and a large emerging AI opportunity tilt the outlook firmly positive.

ARR Growth

Annual recurring revenue climbed 21% year over year to $493 million in Q1 2026, underscoring the durability of Cellebrite’s subscription model. Sequential ARR growth of $12 million supported management’s decision to reaffirm full‑year guidance despite a seasonally tricky first quarter.

Revenue and Subscription Momentum

Total revenue rose 19% to $128.3 million, powered by 23% growth in subscription revenue and a clear shift away from lower‑quality streams. Training, hardware and professional services declined, but management framed this as a deliberate mix change toward higher‑margin, more predictable software subscriptions.

Profitability and Cash Generation

Adjusted EBITDA increased 29% to $30.6 million, lifting the margin to 23.9% and showcasing improving operating leverage as the business scales. Trailing‑12‑month free cash flow reached $159 million, a healthy 32% margin, while reported net income matched adjusted EBITDA at $30.6 million, or $0.12 per diluted share.

Genesis AI Early Adoption

Genesis, Cellebrite’s new agentic investigative AI platform, launched on March 16 and quickly attracted more than 500 registered users across over 15 countries in a free beta. Management highlighted feedback that investigations are becoming faster and higher quality and now expects AI‑specific revenue to emerge earlier than originally planned.

Large Investigative AI TAM Estimate

Executives framed Investigative AI as a transformational growth vector, estimating a roughly $12.5 billion addressable market over the next four years. Using conservative share assumptions, they suggested that capturing around 5% of this market could add roughly $600 million in revenue, potentially approaching a doubling of the company’s current size with solid execution.

Guardian Investigate General Availability

Guardian Investigate, Cellebrite’s AI‑powered digital evidence and case management solution, transitioned to full commercial availability and is beginning to gain traction. Management expects adoption to build through the back half of 2026 as agencies modernize workflows and consolidate evidence handling on integrated platforms.

FedRAMP High Authorization

The company secured FedRAMP High Authorization to Operate on May 6, opening the door to more sensitive U.S. federal cloud deployments. Leadership characterized this as a major competitive differentiator in digital forensics and evidence management, particularly for agencies that require the highest security standards.

Market and Regional Momentum

The U.S. federal pipeline expanded 35% year over year, signaling a recovery from earlier budget‑related softness and aligning with the new federal cloud capabilities. EMEA ARR growth accelerated to 25%, with defense and intelligence customers growing in the mid‑30% range, while growth products such as Guardian, Pathfinder, Corellium and Drone Forensics doubled year over year.

Q2 Guidance and Sequential Acceleration

For Q2, Cellebrite guided to ARR of $510–$513 million, implying $17–$20 million in net new ARR and roughly 50% sequential acceleration at the midpoint. Revenue is expected between $130 million and $133 million, up 15–17% year over year, with adjusted EBITDA of $29–$31 million and margins of 22–23%, even after an estimated two‑point FX headwind.

Platform and Unlock Technology Enhancements

New advanced Android and iOS unlock capabilities landed late in the quarter and drew strong customer interest, including straightforward proofs‑of‑concept. Management pointed to demonstrated pricing power for premium unlock services, suggesting these enhancements can deepen wallet share among high‑value investigative users.

Brand and Community Engagement

Cellebrite’s C2C conference grew attendance by more than 20% to roughly 850 participants, reflecting rising community engagement and international reach. The company also leaned into industry philanthropy and outreach, which it believes strengthens brand visibility among law enforcement, defense and intelligence stakeholders.

Q1 ARR Net-New Pace and Seasonality

Net‑new ARR in Q1 was relatively modest as management reiterated that the first quarter is historically the toughest for renewals and expansions. A smaller pool of contract expirations and some deal push‑outs weighed on the headline figure, but executives stressed that underlying demand trends remain intact.

Segment Weakness and Recovery

The U.S. federal segment was essentially flat in 2025 amid budget pressures and organizational changes on the customer side, creating a drag that is only now easing. With a growing pipeline and new federal certifications in place, management expects a stronger rebound, though investors will watch conversion closely.

Acquisition and Integration Costs

The quarter reflected a full period of Corellium operating costs and the impact of the SCG Canada acquisition on cash deployment. Despite these investments, Cellebrite ended with about $535 million in cash, equivalents and investments, roughly unchanged from year‑end 2025, indicating that M&A is being funded from a position of strength.

FX Headwinds

Currency remained a modest drag, with management baking an estimated two‑percentage‑point FX headwind into Q2 guidance. This pressure tempers reported revenue and margin growth, but constant‑currency performance is stronger, and the company does not see FX as altering its underlying strategic trajectory.

Operational Execution Risks

Leadership repeatedly underscored that the next phase hinges on flawless execution, especially for AI offerings, Guardian Investigate and advanced unlocks. Converting enthusiastic early adopters into paying customers at scale and optimizing pricing models introduces uncertainty, making go‑to‑market discipline a key focus area.

Organizational Change

Cellebrite faces a planned leadership transition with the retirement of its Chief Product and Technology Officer effective July 1. A successor has already been appointed as President of Products and Technology and is working through a handover, but investors will monitor continuity in product strategy during this critical AI ramp.

Guidance and Outlook

Looking ahead, management reaffirmed its 2026 thesis and expects growth products to reach about 20% of ARR by year‑end, supported by Genesis and Guardian. With strong cash reserves, a Q1 adjusted EBITDA margin near 24%, a 32% free cash flow margin and a newly quantified $12.5 billion Investigative AI opportunity, Cellebrite is positioning itself for multi‑year expansion, while acknowledging FX and execution as key swing factors.

Cellebrite’s latest call painted a picture of a software company pivoting successfully into AI‑led growth while preserving solid profitability and cash flow. If management can execute on converting early AI traction and federal pipeline strength into sustained ARR growth, the company could see its already healthy metrics meaningfully accelerate over the coming years.